Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV
EGFR Positive Non-small Cell Lung Cancer
EGFR-TKI Sensitizing Mutation

Interventions

DRUG: Firmonertinib 160mg

Sponsor

Peking University Cancer Hospital & Institute